/PRNewswire/ Mileutis, an Israeli-based biopharmaceutical company revolutionizing how farmers and veterinarians treat a range of diseases, today announced.
/PRNewswire/ Mileutis, an Israeli-based biopharmaceutical company revolutionizing how farmers and veterinarians treat a range of diseases, today announced.
Mileutis Ltd. (“Mileutis”), an Israeli biopharmaceutical company which helps mitigate the use of antibiotics in animals through its safe and residue-free immunomodulator peptides, today announced that its CEO, David Javier Iscovich is set to present a corporate presentation at the 39
th Annual J.P. Morgan Healthcare Conference.
Mileutis is developing residue-free natural proteins based on early research conducted at Israel’s Agricultural Research Organization (Volcani Center), and at Mileutis. The company is developing a line of patented biopharmaceuticals that it believes will revolutionize the way veterinarians manage mastitis and treat a wide range of diseases. Mileutis’ claims are supported by statistically significant results in a number of case-controlled, randomized, multi-center clinical trials.
Share this article
Share this article
NESS ZIONA, Israel, Jan. 7, 2021 /PRNewswire/ Mileutis Ltd. ( Mileutis ), an Israeli biopharmaceutical company which helps mitigate the use of antibiotics in animals through its safe and residue-free immunomodulator peptides, today announced that its CEO, David Javier Iscovich is set to present a corporate presentation at the 39
th Annual J.P. Morgan Healthcare Conference.
Mileutis is developing residue-free natural proteins based on early research conducted at Israel s Agricultural Research Organization (Volcani Center), and at Mileutis. The company is developing a line of patented biopharmaceuticals that it believes will revolutionize the way veterinarians manage mastitis and treat a wide range of diseases. Mileutis claims are supported by statistically significant results in a number of case-controlled, randomized, multi-center clinical trials.